drugset
Drugs / Emeramide
last change 9 days ago re-read 3 minutes ago

Emeramide

also known as Emeramida · NBMI

Small molecule

Developed for
beta-thalassemia major · bronchitis · chronic obstructive pulmonary disease · mercury poisoning · multiple system atrophy · progressive supranuclear palsy
Investigated by
EmeraMed · NBMI Science AB

Trials 4

today NCT04092205 · Ph 2 NCT04184063 · Ph 2 NCT03123692 · Ph 2 NCT02486289 · Ph 2
201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT04092205 Nov 2019 → Jul 2020 beta-thalassemia major EmeraMed Completed No outcome recorded
Phase 2 NCT04184063 Sep 2019 → Jul 2020 multiple system atrophy, progressive supranuclear palsy EmeraMed Completed No outcome recorded
Phase 2 NCT03123692 Jan 2017 → May 2018 bronchitis, chronic obstructive pulmonary disease EmeraMed Completed No outcome recorded
Phase 2 NCT02486289 Aug 2015 → Jan 2016 mercury poisoning EmeraMed Completed No outcome recorded

News releases announcing trial results or a regulatory action · 1

DateIssuerRelease
2017-06-29 EmeraMed Results Pilot Study Results: Emeramide (NBMI) in Mercury-Exposed Gold Miners in Zaruma Ecuador emeramed.com ↗

All press releases naming this drug 4 releases

DateIssuerRelease

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 5 sources stand behind the page.

FieldValueCited text
Known as Emeramide ClinicalTrials.gov intervention name — accepted as the source's own label NCT03123692 ↗
2

NCT02486289 ↗

NCT04092205 ↗
Known as Emeramida ChEMBL registry synonym — accepted as the source's own label CHEMBL4297510 ↗
Known as NBMI ClinicalTrials.gov intervention name — accepted as the source's own label NCT04184063 ↗
Modality Small molecule — CHEMBL4297510 ↗
Route Oral “NBMI oral capsules 100mg administered once daily” NCT02486289 ↗